High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

Amyloid plaques are a neuropathological hallmark of Alzheimer's disease (AD), but their relationship to neurodegeneration and dementia remains controversial. In contrast, there is a good correlation in AD between cognitive decline and loss of synaptophysin-immunoreactive (SYN-IR) presynaptic terminals in specific brain regions. We used expression-matched transgenic mouse lines to compare the effects of different human amyloid protein precursors (hAPP) and their products on plaque formation and SYN-IR presynaptic terminals. Four distinct minigenes were generated encoding wild-type hAPP or hAPP carrying mutations that alter the production of amyloidogenic Aβ peptides. The platelet-derived growth factor β chain promoter was used to express these constructs in neurons. hAPP mutations associated with familial AD (FAD) increased cerebral Aβ1–42 levels, whereas an experimental mutation of the β-secretase cleavage site (671M→I) eliminated production of human Aβ. High levels of Aβ1–42 resulted in age-dependent formation of amyloid plaques in FAD-mutant hAPP mice but not in expression-matched wild-type hAPP mice. Yet, significant decreases in the density of SYN-IR presynaptic terminals were found in both groups of mice. Across mice from different transgenic lines, the density of SYN-IR presynaptic terminals correlated inversely with Aβ levels but not with hAPP levels or plaque load. We conclude that Aβ is synaptotoxic even in the absence of plaques and that high levels of Aβ1–42are insufficient to induce plaque formation in mice expressing wild-type hAPP. Our results support the emerging view that plaque-independent Aβ toxicity plays an important role in the development of synaptic deficits in AD and related conditions.

[1]  B. Ghetti,et al.  A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.

[2]  Bruce A. Yanker New clues to Alzheimer's disease: Unraveling the roles of amyloid and tau , 1996, Nature Medicine.

[3]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[4]  Fred H. Gage,et al.  Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP-43 in the dentate gyrus of the adult rat , 1991, Experimental Neurology.

[5]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[6]  D. Price,et al.  Loss of the Presynaptic Vesicle Protein Synaptophysin in Hippocampus Correlates with Cognitive Decline in Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[7]  S. Younkin Evidence that Aβ42 is the real culprit in alzheimer's disease , 1995 .

[8]  Nobuhiro Suzuki,et al.  Amyloids and Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation (*) , 1996, The Journal of Biological Chemistry.

[9]  L. Mucke,et al.  Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease , 1997, Nature.

[10]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[11]  L. Villa-komaroff,et al.  Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.

[12]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[13]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Riopelle,et al.  Measuring Memory in a Mouse Model of Alzheimer ’ s Disease , 2022 .

[15]  B. Yankner New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. , 1996, Nature medicine.

[16]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Masliah,et al.  Spectrum of human immunodeficiency virus–associated neocortical damage , 1992, Annals of neurology.

[18]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[19]  H. Braak,et al.  Evolution of neuronal changes in the course of Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.

[20]  P. Moran,et al.  Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[22]  Davis Jn nd,et al.  The 'amyloid cascade hypothesis' of AD: decoy or real McCoy? , 1997 .

[23]  Bruce A. Yankner,et al.  Aging renders the brain vulnerable to amyloid β-protein neurotoxicity , 1998, Nature Medicine.

[24]  E. Masliah,et al.  Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. , 1991, The American journal of pathology.

[25]  P. Lansbury,et al.  A detergent-insoluble membrane compartment contains A beta in vivo. , 1998, Nature medicine.

[26]  E. Bigio,et al.  Neocortical Synapse Density and Braak Stage in the Lewy Body Variant of Alzheimer Disease: A Comparison with Classic Alzheimer Disease and Normal Aging , 1998, Journal of neuropathology and experimental neurology.

[27]  M. Mattson,et al.  Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein , 1993, Neuron.

[28]  C. Masters,et al.  The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth , 1992, Neuron.

[29]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[30]  B Carragher,et al.  Three-Dimensional Analysis of the Relationship Between Synaptic Pathology and Neuropil Threads in Alzheimer Disease , 1992, Journal of neuropathology and experimental neurology.

[31]  W. Honer,et al.  Correlations of synaptic and pathological markers with cognition of the elderly , 1995, Neurobiology of Aging.

[32]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[33]  L. Mucke,et al.  Levels and Alternative Splicing of Amyloid β Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease (*) , 1995, The Journal of Biological Chemistry.

[34]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[35]  L. Mucke,et al.  Synaptotrophic effects of human amyloid β protein precursors in the cortex of transgenic mice , 1994, Brain Research.

[36]  Cappai,et al.  The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide , 1999 .

[37]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[38]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[39]  K. Murakami,et al.  Formation of β-amyloid protein deposits in brains of transgenic mice , 1991, Nature.

[40]  J. C. Chisholm,et al.  The 'amyloid cascade hypothesis' of AD: decoy or real McCoy? , 1997, Trends in neurosciences.

[41]  W. Rosenblum The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. , 1997, Journal of neuropathology and experimental neurology.

[42]  C. Masters,et al.  The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I) , 1996, Science.

[43]  D. Selkoe,et al.  Generation of amyloid β protein from its precursor is sequence specific , 1995, Neuron.

[44]  Christina A. Wilson,et al.  Intracellular APP Processing and Aβ Production in Alzheimer Disease , 1999 .

[45]  D. Price,et al.  Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.

[46]  Matthias Orth,et al.  Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration , 1999, The Journal of Neuroscience.

[47]  E. Masliah,et al.  Synaptic and neuritic alterations during the progression of Alzheimer's disease , 1994, Neuroscience Letters.

[48]  B. Hyman,et al.  Abeta associated neuropil changes: correlation with neuronal loss and dementia. , 1998, Journal of neuropathology and experimental neurology.

[49]  P. Greengard,et al.  Generation and Regulation of β‐Amyloid Peptide Variants by Neurons , 1998 .

[50]  T. Katada,et al.  Intrinsic signaling function of APP as a novel target of three V642 mutations linked to familial Alzheimer's disease. , 1996, The EMBO journal.

[51]  D. Selkoe,et al.  Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Masliah,et al.  A simple dot-immunobinding assay for quantification of synaptophysin-like immunoreactivity in human brain. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[53]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[54]  E. Masliah,et al.  Cortical Synaptic Density is Reduced in Mild to Moderate Human Immunodeficiency Virus Neurocognitive Disorder , 1999, Brain pathology.

[55]  L. Mucke,et al.  Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. , 1994, Nature.

[56]  L. Mucke,et al.  Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[57]  R. D'Hooge,et al.  Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein. , 1996, Neuroreport.

[58]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[59]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[60]  R S Turner,et al.  Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. , 1996, The Journal of biological chemistry.

[61]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Younkin,et al.  Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.

[63]  P. Lansbury,et al.  A detergent-insoluble membrance compartment contains Aβ in vivo , 1998, Nature Medicine.

[64]  L. Mucke,et al.  Amyloid Protein Precursor Stimulates Excitatory Amino Acid Transport , 1998, The Journal of Biological Chemistry.

[65]  P. Greengard,et al.  Generation and regulation of beta-amyloid peptide variants by neurons. , 1998, Journal of neurochemistry.

[66]  S. Novosel,et al.  Alzheimer's disease: a review of the disease, its epidemiology and economic impact. , 1998, Archives of gerontology and geriatrics.

[67]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[68]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[69]  S. M. Sumi,et al.  The Mean Aβ Load in the Hippocampus Correlates with Duration and Severity of Dementia in Subgroups of Alzheimer Disease , 1997, Journal of Neuropathology and Experimental Neurology.

[70]  W. Honer,et al.  Regional synaptic pathology in Alzheimer's disease , 1992, Neurobiology of Aging.

[71]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[72]  T. Holzman,et al.  Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. , 1994, Biophysical journal.

[73]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.